#### **Purpose**

Establish revised policy regarding blood donor screening, deferral and lookback for West Nile Virus. This policy applies to collections of Whole Blood, blood components (including recovered plasma), Source Plasma and Source Leukocytes collected from allogeneic and autologous donors intended either for use in transfusion or for further manufacture into injectable and non-injectable products. Services should update applicable Standardized Operating Procedures (SOP) in accordance with (IAW) this policy.

#### **Background**

WNV is primarily transmitted in birds through mosquito bites. Humans are incidental hosts. WNV is associated with human encephalitis and meningitis. In 2002, a major outbreak of WNV was detected in many parts of the United States. The number of human cases of WNV illness in 2002 totaled 4161 and 277 deaths were reported as of March 12, 2003. The 2002 WNV epidemic involved the first documented cases of WNV transmission through blood transfusion, organ transplantation, intrauterine infection, and possibly breastfeeding. Since 80% of persons infected with WNV do not develop any illness and remain asymptomatic, even while transiently viremic, careful predonation screening and WNV testing of blood and plasma donors for WNV is necessary to reduce the risk of WNV infection through blood transfusion.

#### **Definitions**

The following definitions apply to WNV in this policy:

Term	Definition	
Symptoms of WNV Infection	<ul> <li>Measured fever [temperature greater than 100.4 °F (38°C)] AND</li> <li>One or more flu-like symptom suggestive of WNV infection (e.g. headache, eye pain, body aches, generalized weakness, new generalized skin rash, swollen lymph nodes)</li> <li>Additional information available on CDC website: <a href="http://www.cdc.gov/ncidod/dvbid/westnile/clinical guidance.htm">http://www.cdc.gov/ncidod/dvbid/westnile/clinical guidance.htm</a> OR</li> <li>www.cdc.gov/ncidod/dvbid/westnile/city_states.htm</li> </ul>	

#### **Definitions** (continued)

Term	Definition	
<b>Measured Fever</b>	• Temperature greater than 100.4 °F (38°C)	
Medical Diagnosis of WNV Infection	<ul> <li>Current or recent illness compatible with WNV AND</li> <li>Positive test for WNV IgM antibodies</li> </ul>	
Suspect Donation(s)	The collection(s) from which an infected recipient received a blood component	
Donors At Risk of Transmitting WNV	<ul> <li>Measured fever with headache or with other WNV symptoms within 7 days prior to and 14 days after donation</li> <li>Recent diagnosis of WNV infection AND donated blood within 14 days prior to and 28 days after onset of symptoms</li> <li>Recent confirmed positive test for WNV NAT</li> <li>Determined to be potentially associated with a case of transfusion transmitted WNV</li> </ul>	
Donors Potentially Associated with Transfusion Transmitted WNV Patients Potentially Associated with Transfusion Transmitted WNV	<ul> <li>A recipient is later diagnosed with WNV AND</li> <li>The recipient received blood components from the donor within 28 days before the onset of symptoms in the recipient.</li> <li>Diagnosis of WNV infection AND</li> <li>Received blood transfusions or organs within 28 days preceding onset of symptoms</li> </ul>	

### **Donor Screening** and **Deferral**

Perform the following 8 steps to screen the donor for possible WNV infection.

Step	Action	
1	Provide each allogeneic and autologous donor with the WNV	
	information contained in Attachment A. <b>NOTE</b> : Services may	
	choose to modify the format of Attachment A or combine the	
	information with other donor information sheets.	

#### **Donor Screening and Deferral** (continued)

Step	Action		
2	Ask the donor if they read and understood the WNV information		
	provided to them.		
	If the donor	Then	
	Understands the WNV	Continue	
	information provided		
	Does NOT understand the	Explain and answer any	
	WNV information provided	questions for the donor	
3	Ask the donor the following WN	IV screening question: "In the past	
	7 days, have you had an unexp	lained, measured fever of greater	
	than 100.4 °F (38°C) associate	ed with a headache"?	
4	Determine whether or not the do	onor is deferred for possible WNV:	
	If the donor	Then the donor is	
	Answers <b>NO</b> to the WNV	NOT deferred for WNV infection	
	screening question		
	Answers <b>YES</b> to the WNV	<b>Deferred for</b> 28 days from the	
	screening question	date of interview	
	Has a history of or reports	<b>Deferred temporarily</b> until re-	
	a confirmed positive test	instated in accordance with the	
	for WNV NAT on any	WNV NAT testing protocol and	
	previous donation	Service-specific SOPs. The donor	
	may NOT be re-instated any		
		sooner than 28 days after the	
		date of the confirmed positive	
	TX 1	donation.	
	Had a recent diagnosis of	<b>Deferred for</b> 28 days from the	
	WNV infection	onset of illness or 14 days after	
		the condition is considered to be	
		resolved, whichever date is later.	

#### **Donor Screening and Deferral** (continued)

Step	Action		
		_	
	If the donor	Then the donor is	
	Has been notified that a previous	<b>Deferred for</b> 28 days	
	donation is potentially associated	from the date of the	
	with transfusion transmitted WNV	implicated donation	
	infection		
5	Document whether or not the donor is d	eferred for possible WNV	
	infection IAW Service-specific SOPs.		
6	If donor is deferred, enter deferral in DE	BSS using DBSS Temporary	
	Deferral Code 906.		
7	Encourage donors to report any informa		
	becomes known to them after their dona	ation:	
	• Unreported measured fever of greater	than 100.4 °F (38°C)	
	associated with headache, occurring w	yithin 7 days prior to donation.	
	• Unexplained measured fever of greater than 100.4 °F (>38°C)		
	associated with headache or associated	d with other symptoms	
	suggestive of WNV infection, occurring within 14 days after		
	donation.		
	Notification that one of their blood donations tested confirmed		
	positive for WNV NAT.		
	• Recent diagnosis of WNV infection.		
	• Notification that one of their donations is suspected of being		
	potentially associated with transfusion transmitted WNV infection		
	in a transfusion recipient.		

#### **WNV Testing**

When WNV test kits are available for use, perform the following 5 steps to test all homologous and autologous donors for possible WNV infection.

**NOTE:** Tests will be performed using the nucleic acid testing (NAT) methodology, will initially be performed under investigational procedures, and will subsequently be performed using a licensed test when available.

#### WNV Testing (continued)

Step	Action		
1	Test the donation for WNV in accordance with NAT testing protocols and Service-specific SOPs.		
2	Determine if the donor is confirmed positive for WNV in accordance with NAT testing protocols.		
3	Use the following criteria for probased on the results of WNV NA	duct management and donor deferral T.	
	If the donor Then		
	Tests <b>negative</b> for WNV NAT	Make blood components available and do not defer donor	
	Tests confirmed positive for WNV NAT	Quarantine and destroy all components     Temporarily defer donor until re-instated in accordance with WNV NAT testing protocols and Service-specific SOPs. The donor may NOT be re-instated any sooner than 28 days after the date of the confirmed positive donation.	
4	If donor is deferred, document donor deferral for WNV NAT in accordance with Service-specific SOPs.		
5	If donor is deferred, enter deferral in DBSS using DBSS Temporary Deferral Code 906.		

#### Lookback and Post Donation Information

Perform the following 7 steps for donor and patient lookback when a donor tests confirmed positive for WNV NAT or WNV related post donation information (PDI) is received.

**NOTE:** Quarantine and retrieval of previously collected components applies to collections of Whole Blood and blood components intended for transfusion, as well as <u>unpooled</u> Source plasma, recovered plasma, and Source Leukocytes intended for further manufacturing into injectable and non-injectable products. <u>Quarantine and retrieval is not recommended for those products that have been pooled for fractionation</u>.

Step	Action	
1	Perform the following steps for p	roduct identification/retrieval:
	If PDI is received about	Then promptly identify and locate all in-date products
	<ul> <li>Donors with mild symptoms of upper respiratory infection unassociated with fever OR</li> <li>Donors with only mosquito bites</li> </ul>	NOT required or recommended.
	Donors with an unexplained measured fever of >100.4 °F (>38°C) associated with headache or associated with other symptoms suggestive of WNV infection, occurring within 7 days prior to or 14 days after donation.	Collected within 14 days prior to and 28 days after the onset of symptoms in donor.
	Donors testing confirmed positive for WNV NAT on a blood donation.	Collected within 14 days prior to and 28 days after the date of the initial positive blood donation.
	Donors with a recent diagnosis of WNV infection.	Collected within 14 days prior to and 28 days after the onset of illness in the donor.

#### Lookback and Post Donation Information (continued)

If PDI is received about	t Then promptly identify and
	locate all in-date products
Patients with recent diagr of WNV infection who received blood transfusio or organ donations within 28 days preceding the ons of WNV symptoms.	nosis Of all "suspect" donations that were transfused to the WNV patient <b>AND</b> all previous donations from the
Donors suspected of bein potentially associated wit transfusion transmitted W infection in a recipient	ng Associated with "suspect" th donation and all previous
Perform the following steps notification, and recipient no	s for product management, consignee otification:
If products are/were	Then
Available	Quarantine and destroy all blood products. Document disposition.
Shipped	Notify consignee(s) to quarantine and destroy all products.  Document notification.
Destroyed	Document disposition.
Transfused <b>AND</b> donor illness is a medical diagnosis of WNV	Identify and Notify prior recipients of the potential WNV transfusion risk. (Relevant units are those dating from 14 days prior through 28 days after the onset of illness of the donor).
	received blood transfusion or organ donations within 28 days preceding the on of WNV symptoms.  Donors suspected of being potentially associated witeransfusion transmitted Winfection in a recipient.  Perform the following steps notification, and recipient in Available  Shipped  Destroyed  Transfused AND donor illness is a medical

#### Lookback and Post Donation Information (continued)

Step	Action		
	If products are/were	Then	
	Transfused but donor	Do NOT notify prior recipients of	
	illness is <b>NOT</b> medical	blood components collected from	
	diagnosis of WNV	that donor.	
	Transfused and	Do NOT notify prior recipients of	
	potentially associated	blood components collected from	
	with transmission of	that donor	
	WNV to a transfusion		
	recipient, but NOT		
	<b>confirmed</b> through		
	epidemiological		
	investigation		
	Transfused and the	<u>Identify</u> and notify prior recipients	
	likely source of	of blood components collected	
	transmission of WNV	from that donor of the potential	
	to a transfusion	WNV transfusion risk. (Relevant	
	recipient, AND	units are those dating from 28 days	
	confirmed through	prior to 28 days after the date of	
	epidemiological	the donation that is implicated in	
	investigation	transmission of WNV).	
3	IAW Service procedures, notify local public health personnel and		
		ces of donors diagnosed with or	
	, <u>.</u>	NV and of any transfusion recipients	
	potentially at risk for WNV transfusion transmitted infection.		
4	Follow Service directed protocols for shipment of patient samples		
	for further study.		
	• Additional information on laboratory samples for CDC can be		
	found at <a href="http://www.cdc.gov/ncidod/dvbid/westnile/clinical">http://www.cdc.gov/ncidod/dvbid/westnile/clinical</a>		
	guidance.htm		
	If samples are	Then	
	Needed for further testing		
	NOT needed	Discard IAW local policy	
	1VOT RECUCU	Discard IAW local policy	
	L		

#### Lookback and Post Donation Information (continued)

Step	Action		
5	Document PDI and lookback IAW Service-specific SOPs.		
6	If donor is deferred, enter donor of	deferral in DBSS using temporary	
	deferral code 906. (See Donor So	creening and Deferral section of	
	the document, for appropriate do	nor deferral criteria)	
7	Submit Biologic Product Deviation	on (BPD) reports, IAW Service	
		on information related to WNV in	
	cases where:		
	A suspect blood product	Then a BPD is	
	Was retrieved and	Required, contact Service	
	quarantined as a result of a Blood Program Office		
	WNV PDI report		
	Was transfused and resulted Required, contact Service		
	in notification of a Blood Program Office		
	transfusion recipient		
	Was transfused and resulted	Required, contact Service	
	in the fatality of a transfusion	Blood Program Office	
	recipient (SBPO)		
	NOT distributed NOT required		

### **CDC Reporting Requirements**

To assist in identification of other possible cases of WNV infection potentially associated with transfusion, the FDA also requires that:

If	And	Then
Patient is diagnosed with WNV infection	Patient has received blood transfusion or organs within 28 days preceding onset of WNV symptoms	<ul> <li>Possible transfusion transmission of WNV should be reported to the CDC through local public health authorities. AND</li> <li>Serum or tissue samples should be retained for later studies</li> </ul>

#### **CDC Reporting Requirements** (continued)

If	And	Then
Donor is diagnosed with WNV infection	Donor had onset of WNV symptoms within 14 days of blood or organ donation	Possible transfusion transmission of WNV should be reported to the CDC through local public health authorities

### Labeling of Products

Quarantined products that were distributed for research or intended for further manufacturing into Non-Injectable products, must be labeled consistent with recommended labeling described below as applicable:

- "Biohazard" OR
- "Collected from a donor determined to be at risk for West Nile Virus" **OR**
- "Collected from a donor positive for evidence of infection with West Nile Virus" **OR**
- "For laboratory research use only" **OR**
- "Intended only for further manufacturing into non-injectable products"

#### **Donor Information About West Nile Virus (WNV)**

#### What is WNV?

West Nile Virus infection has been associated with human encephalitis and meningitis. Throughout 2001 and 2002, WNV spread to about half of the US. In 2002, over 4000 cases of WNV illness and 277 deaths were reported. 99% of human cases in 2002 occurred between 2 July and 30 October.

### How can I get WNV?

WNV is a mosquito borne virus that is primarily transmitted in birds through mosquito bites. WNV can also be transmitted from birds to humans through mosquito bites.

## Can WNV be passed by blood transfusion?

Yes. The 2002 WNV epidemic involved the first documented cases of WNV transmission through blood transfusion, organ transplantation, from mothers to infants during pregnancy, and possibly during breastfeeding.

### Can I donate blood today?

The Food and Drug Administration has recommended that donors who have a risk of being infected with WNV do not donate blood for a short interval.

You may NOT donate blood if you	You must wait
Had an unexplained measured fever of greater than	At least 28 days from today's attempted
100.4 °F (38°C) associated with a headache within	donation date
the last 7 days <b>OR</b>	
Have been recently diagnosed with WNV infection	At least 28 days from the first day of
OR	WNV symptoms or until 14 days after
	the WNV illness is resolved
Have been notified that one of your blood donations	Until you are notified that you are
tested positive for WNV	eligible to donate again, but at least 28
	days after the date of the confirmed
	positive donation.
Have been notified that one of your previous blood	At least 28 days after the date of that
donations is the potential cause of WNV infection in	previous donation.
a patient that has been transfused with your blood	

## After you donate blood!

Thank for ensuring the safety of the blood supply! As long as you are well and remain well, you need not take any other measures. However you should notify the blood donor center and see your doctor if:

- In the 14 days after your donation, you become ill with a fever of 100.4 °F or higher **AND** have cold-flu symptoms **OR**
- You later find out that you meet any of the other restrictions above.